Abstract 103P
Background
Microsatellite instability (MSI) is a powerful predictor for the efficacy of immune checkpoint inhibitor (ICI) therapy across tumor types. Although conventional MSI testing strategies are widely used, NGS represents a promising tool for MSI detection. We have developed and validated the NGS test system for MSI detection in solid tumors.
Methods
The following sample types were selected for validation of our test system: G1 - archive FFPE tumor samples collected from patients with known MSI status; G2 - archive paired (FFPE/ctDNA) samples collected from patients with tumors where MSI is uncommon (<1%); G3 - paired (FFPE/ctDNA) MSI+ samples. All FFPE samples were tested using the gold standard (5-loci PCR, 4-antibody IHC). Samples were considered MSI+ if PCR or IHC were positive; MSI- when both were negative. Detection of MSI was performed using k-mer distributions of 28 loci.
Results
A total of 123 samples for 109 patients were analyzed - 77 (62.6%) FFPE, 46 (37.4%) ctDNA; 6 patients had paired samples. A total of 30 (FFPE, 83% CRC), 72 (41 FFPE, 31 ctDNA; 62.3% NSCLC) and 21 (6 patients; 6 FFPE, 15 ctDNA; 66.7% CRC) were selected for G1, G2 and G3, respectively. Rate of agreement (κ) between NGS and gold standard in G1 was 0.8 (95% CI, 0.58-1) [κ for NGS/PCR 0.93 (95% CI, 0.8-1)], and 1 in G3. In G2, 100% of samples were MSS following NGS. In G3, for all 6 samples there were no disagreements between NGS and gold standard. Across all analyzed FFPE samples, κ between NGS and gold standard was 0.9 (95% CI 0.88-0.92). When comparing results of PCR and IHC (FFPE samples), low concordance was noted (κ=0.5, 95% CI, 0.22-0.78). High concordance was observed between PCR and NGS (κ=0.94, 95% CI, 0.83-1). Concordance of IHC and NGS was low (κ=0.55, 95% CI, 0.28-0.83). Sensitivity / specificity of NGS vs IHC in detecting MSI were 76.2% / 80%. Sensitivity / specificity of NGS vs PCR were 95.5% / 100%. Sensitivity / specificity of NGS in detecting MSI using ctDNA vs FFPE were 100% / 100%.
Conclusions
Low concordance was observed between IHC and PCR for MSI detection (κ=0.5, 95% CI, 0.22-0.78). Concordance of PCR and NGS was high (κ=0.94, 95% CI, 0.83-1); concordance between IHC and NGS was lower (κ=0.55, 95% CI, 0.28-0.83). Sensitivity of MSI detection using ctDNA was 100%.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
This study was supported by Russian Science Foundation (grant № 22-75-10154).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - Investigating the influence of extrachromosomal DNA in the progression of non-small cell lung cancer through the TRACERx and PEACE studies
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
Presenter: Diego Gomez Puerto
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Exploring miR-205 and miR-296 as salivary biomarkers and potential therapeutic targets in oral cancer
Presenter: Thaís Moré Milan
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence
Presenter: Jinhwa Hong
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Differential expression of discriminative markers in matched invasion fronts and tumour buds in CRC
Presenter: Laura Grech
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Transcriptome profiling highlights distinct gene signatures in HER2 high (HER2 3+) and HER 2 low (Her2 1+/2+) breast cancers
Presenter: Tamanna Thakur
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - MiR-155 promotes breast cancer progression by upregulating cancer stemness
Presenter: Jeonghee Han
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study
Presenter: Christophe Mapendano
Session: Cocktail & Poster Display session
Resources:
Abstract